<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164719</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-CY-F110</org_study_id>
    <nct_id>NCT04164719</nct_id>
  </id_info>
  <brief_title>Dose-Proportionality and Food Effect Study of TNX-102 SL</brief_title>
  <official_title>A Single-dose, Randomized, Open-label, 3-way Crossover Study to Evaluate the Dose-proportionality and Food Effect of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tonix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tonix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single center, single-dose, randomized, open-label, 3-period, crossover,
      dose-proportionality and food-effect study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Actual">December 24, 2019</completion_date>
  <primary_completion_date type="Actual">December 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of TNX-102 SL 5.6 mg versus TNX-102 SL 2.8 mg under fasting conditions</measure>
    <time_frame>Day 1 to Day 6</time_frame>
    <description>Blood samples are collected from pre-dose on Day 1 up until Day 6 (144 hours post-dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of TNX-102 SL 5.6 mg versus TNX-102 SL 5.6 mg under fed conditions</measure>
    <time_frame>Day 1 to Day 6</time_frame>
    <description>Blood samples are collected from pre-dose on Day 1 up until Day 6 (144 hours post-dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) of TNX-102 SL 2.8 mg versus TNX-102 SL 5.6 mg under fasting conditions</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Blood samples are collected from pre-dose on Day 1 up until Day 15 (360 hours post-dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) of TNX-102 SL 5.6 mg under fasted and fed conditions</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Blood samples are collected from pre-dose on Day 1 up until Day 15 (360 hours post-dose)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNX-102 SL 2.8 mg, under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNX-102 SL</intervention_name>
    <description>Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>cyclobenzaprine HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, non-smoker, ≥18 and ≤65 years of age, with Body Mass Index (BMI) &gt;18.5
             and &lt;30.0 kg/m2

          -  Females of childbearing potential must be willing to use a medically acceptable method
             of birth control throughout the study

          -  Capable of consent

        Exclusion Criteria:

          -  Any clinically significant abnormality or abnormal laboratory test results found
             during medical screening

          -  Positive hepatitis B, hepatitis C, HIV, urine drug screen, urine cotinine test, or
             alcohol breath test at screening

          -  History of allergic reactions to cyclobenzaprine, any of the formulation components,
             or other related drugs

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days
             prior to the first study drug administration

          -  Positive pregnancy test at screening

          -  Clinically significant electrocardiogram (ECG) abnormalities or vital sign
             abnormalities at screening

          -  History of significant alcohol or drug abuse within one year prior to screening

          -  Participation in a clinical trial involving the administration of an investigational
             or marketed drug within 30 days prior to the first dosing or concomitant participation
             in an investigational study involving no drug administration

          -  Use of medication other than topical products without significant systemic absorption
             and hormonal contraceptives

          -  Donation of plasma within 7 days prior to dosing, or significant loss of blood within
             54 days of dosing.

          -  Abnormal hemoglobin and hematocrit levels at screening

          -  Breast-feeding subject

          -  Presence of orthodontic braces or orthodontic retention wires, or any physical
             findings in the mouth or tongue that would be likely to interfere with successful
             completion of the dosing procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Audet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Contract Research Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canada, Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclobenzaprine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

